BR112022007944A2 - Anticorpos trem2 e usos dos mesmos - Google Patents
Anticorpos trem2 e usos dos mesmosInfo
- Publication number
- BR112022007944A2 BR112022007944A2 BR112022007944A BR112022007944A BR112022007944A2 BR 112022007944 A2 BR112022007944 A2 BR 112022007944A2 BR 112022007944 A BR112022007944 A BR 112022007944A BR 112022007944 A BR112022007944 A BR 112022007944A BR 112022007944 A2 BR112022007944 A2 BR 112022007944A2
- Authority
- BR
- Brazil
- Prior art keywords
- trem2 antibodies
- trem2
- antibodies
- diseases
- relates
- Prior art date
Links
- 101000795117 Homo sapiens Triggering receptor expressed on myeloid cells 2 Proteins 0.000 title abstract 3
- 102100029678 Triggering receptor expressed on myeloid cells 2 Human genes 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
ANTICORPOS TREM2 E USOS DOS MESMOS. A presente invenção refere-se aos anticorpos TREM2 e usos dos mesmos para tratar doenças como as doenças neurodegenerativas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962939097P | 2019-11-22 | 2019-11-22 | |
| PCT/US2020/060663 WO2021101823A1 (en) | 2019-11-22 | 2020-11-16 | Trem2 antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022007944A2 true BR112022007944A2 (pt) | 2022-07-12 |
Family
ID=73790267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022007944A BR112022007944A2 (pt) | 2019-11-22 | 2020-11-16 | Anticorpos trem2 e usos dos mesmos |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20220281975A1 (pt) |
| EP (1) | EP4061842A1 (pt) |
| JP (1) | JP7368624B2 (pt) |
| KR (1) | KR20220084152A (pt) |
| CN (1) | CN114667295B (pt) |
| AU (1) | AU2020387380A1 (pt) |
| BR (1) | BR112022007944A2 (pt) |
| CA (1) | CA3159055A1 (pt) |
| CO (1) | CO2022006708A2 (pt) |
| CR (1) | CR20220228A (pt) |
| DO (1) | DOP2022000104A (pt) |
| EC (1) | ECSP22041169A (pt) |
| IL (1) | IL293018A (pt) |
| JO (1) | JOP20220119A1 (pt) |
| MX (1) | MX2022006145A (pt) |
| PE (1) | PE20221337A1 (pt) |
| WO (1) | WO2021101823A1 (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190248A1 (ar) | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
| WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6669749B2 (ja) | 2014-08-08 | 2020-03-18 | アレクトル エルエルシー | 抗ｔｒｅｍ２抗体及びその使用方法 |
| SG10201912150TA (en) * | 2015-10-06 | 2020-02-27 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
| US10941200B2 (en) | 2016-07-22 | 2021-03-09 | Deutsches Zentrum Für Neurodegenerative Erkrankungen Ev | TREM2 cleavage modulators and uses thereof |
| KR20200033794A (ko) | 2017-08-03 | 2020-03-30 | 알렉터 엘엘씨 | 항-trem2 항체 및 이의 사용 방법 |
| WO2019055841A1 (en) | 2017-09-14 | 2019-03-21 | Denali Therapeutics Inc. | ANTI-TREM2 ANTIBODIES AND METHODS OF USE |
| CR20200303A (es) * | 2017-12-12 | 2020-12-23 | Pionyr Immunotherapeutics Inc | Anticuerpos anti-trem2 y métodos relacionados |
-
2020
- 2020-11-16 KR KR1020227016708A patent/KR20220084152A/ko active Search and Examination
- 2020-11-16 CR CR20220228A patent/CR20220228A/es unknown
- 2020-11-16 BR BR112022007944A patent/BR112022007944A2/pt not_active Application Discontinuation
- 2020-11-16 CN CN202080079451.2A patent/CN114667295B/zh active Active
- 2020-11-16 JP JP2022529507A patent/JP7368624B2/ja active Active
- 2020-11-16 PE PE2022000821A patent/PE20221337A1/es unknown
- 2020-11-16 EP EP20821525.1A patent/EP4061842A1/en active Pending
- 2020-11-16 WO PCT/US2020/060663 patent/WO2021101823A1/en active Application Filing
- 2020-11-16 JO JOP/2022/0119A patent/JOP20220119A1/ar unknown
- 2020-11-16 AU AU2020387380A patent/AU2020387380A1/en active Pending
- 2020-11-16 MX MX2022006145A patent/MX2022006145A/es unknown
- 2020-11-16 IL IL293018A patent/IL293018A/en unknown
- 2020-11-16 CA CA3159055A patent/CA3159055A1/en active Pending
-
2022
- 2022-05-05 US US17/737,439 patent/US20220281975A1/en active Pending
- 2022-05-19 DO DO2022000104A patent/DOP2022000104A/es unknown
- 2022-05-20 CO CONC2022/0006708A patent/CO2022006708A2/es unknown
- 2022-05-20 EC ECSENADI202241169A patent/ECSP22041169A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL293018A (en) | 2022-07-01 |
| CA3159055A1 (en) | 2021-05-27 |
| EP4061842A1 (en) | 2022-09-28 |
| WO2021101823A1 (en) | 2021-05-27 |
| CR20220228A (es) | 2022-06-08 |
| JOP20220119A1 (ar) | 2023-01-30 |
| JP2023502460A (ja) | 2023-01-24 |
| CN114667295A (zh) | 2022-06-24 |
| JP7368624B2 (ja) | 2023-10-24 |
| CO2022006708A2 (es) | 2022-05-31 |
| US20220281975A1 (en) | 2022-09-08 |
| AU2020387380A1 (en) | 2022-05-26 |
| DOP2022000104A (es) | 2022-07-31 |
| PE20221337A1 (es) | 2022-09-13 |
| MX2022006145A (es) | 2022-06-17 |
| ECSP22041169A (es) | 2022-06-30 |
| KR20220084152A (ko) | 2022-06-21 |
| CN114667295B (zh) | 2024-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019002535A1 (es) | Composiciones para modular la expresión de sod-1.(divisional solicitud 201801897). | |
| BR112018010464A2 (pt) | formulações farmacêuticas tópicas para tratar condições inflamatórias relacionadas | |
| BR112018002432A2 (pt) | anticorpos de ligação à il-8 e usos dos mesmos | |
| ECSP17018120A (es) | Triazolopirazinonas como inhibidores de pde1 | |
| CO2017004314A2 (es) | Compuestos anti-tnf | |
| PE20171094A1 (es) | Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda | |
| EA201891539A1 (ru) | Соединения, ингибирующие металлоферменты | |
| BR112016028045A8 (pt) | biopolímeros modificados, e seus métodos de produção | |
| CL2017002719A1 (es) | Imidazopirazinonas como inhibidores de pde1 | |
| EA201690007A1 (ru) | Соединения, ингибирующие металлоферменты | |
| BR112018003741A2 (pt) | composições biofarmacêuticas | |
| CL2017001135A1 (es) | Anticuerpos mejorados contra il-6 | |
| BR112018011633A2 (pt) | inibidores de aza-benzimidazol de pad4 | |
| BR112018012304A2 (pt) | composições e métodos para diminuir expressão de tau | |
| BR112018003526A2 (pt) | métodos de tratamento de doenças inflamatórias | |
| BR112018002382A8 (pt) | Novos anticorpos anti-gvpi humano e usos dos mesmos | |
| BR112022007944A2 (pt) | Anticorpos trem2 e usos dos mesmos | |
| SV2018005613A (es) | Agentes, usos y metodos para el tratamiento | |
| MX2020009130A (es) | Anticuerpos terapéuticos anti-spla2-gib y los usos de los mismos. | |
| BR112015011798A2 (pt) | métodos e composições para tratar doenças neurodegenerativas | |
| BR112016022575A2 (pt) | Composições e métodos para o tratamento de doenças neurodegenerativas | |
| BR112018067693A2 (pt) | compostos de selenogalactosídeo para a prevenção e tratamento de doenças associadas com galectina e usos dos mesmos | |
| BR112021011124A2 (pt) | Anelossomos e métodos de uso | |
| BR112018068671A2 (pt) | anticorpos monoclonais neutralizantes para il-25 e usos dos mesmos | |
| BR112019006310A2 (pt) | método para fabricar digliceróxido de cálcio |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |